"10.1371_journal.pone.0060094","plos one","2013-03-20T00:00:00Z","Satish Keshav; Tomáš Vaňásek; Yaron Niv; Robert Petryka; Stephanie Howaldt; Mauro Bafutto; István Rácz; David Hetzel; Ole Haagen Nielsen; Séverine Vermeire; Walter Reinisch; Per Karlén; Stefan Schreiber; Thomas J Schall; Pirow Bekker; the Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 (PROTECT-1) Study Group","John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; Hepato-Gastroenterologie HK, Hradec Králové, Czech Republic; Rabin Medical Center, Petach Tikva, Israel; NZOZ Vivamed, Zespół Lekarzy Specjalistów, Warszawa, Poland; Praxis für Innere Medizin, Hamburg, Germany; Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda., Goiânia, Brazil; Petz Aladár County and Teaching Hospital, Győr, Hungary; Royal Adelaide Hospital, Adelaide, Australia; Department of Gastroenterology, Herlev Hospital, Herlev, Denmark; UZ Gasthuisberg, Leuven, Belgium; Allgemeines Krankenhaus Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Vienna, Austria; Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden; Department of Medicine I, Christian Albrechts University, University Hospital Schleswig Holstein, Kiel, Germany; ChemoCentryx, Inc., Mountain View, California, United States of America","¶ The investigators who contributed to the Prospective Randomized Oral-Therapy Evaluation in Crohns Disease Trial-1 (PROTECT-1) are listed in Appendix S1.","The authors have the following interests. P. Bekker is an employee and shareholder of ChemoCentryx, and T. Schall is an employee, shareholder, and holder of patent number US2005-0137179 on bis-aryl sulfonamides., the funder of this clinical trial. Robert Petryka, is an employee of NZOZ Vivamed, which is a network of medical care specialists. NZOZ Vivamed does not have any commercial interest or stake in the drug candidate, CCX282-B, tested in the clinical trial which is the subject of this manuscript. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","03","Satish Keshav","SK",16,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
